EC Pharmacology and Toxicology

Research Article Volume 11 Issue 3 - 2023

Metabolic Syndrome Predictors and Cancer Incidence against the Backdrop of a Rising Gradient in the Burden of Alcoholism in Men in 160 Countries 2004

Ludmila Radkevich1* and Dariya Radkevich2

1Doctor of Biological Sciences, Chief Researcher, Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences CTP PCP RAS, Moscow, Russia
2Specialist (Physicist), Analyst, Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences CTP PCP RAS, Moscow, Russia

*Corresponding Author: Ludmila Radkevich, Doctor of Biological Sciences, Chief Researcher, Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences CTP PCP RAS, Moscow, Russia.
Received: May 18, 2022; Published: February 09, 2023



Objective: To study the risk factors for the burden of cancer and predictors of the metabolic syndrome against the background of the gradient of alcoholism in 160 countries of the world 2004.

Materials and Methods: For the purposes of the study, a database of 160 countries on the burden of alcoholism, 14 types of cancer (ICD-10 codes) and 8 predictors of metabolic syndrome were created. Burden of disease (DALY) data for men in 160 countries, standardized by sex and age, were selected from the 2004 GBD database. The U-Mann-Whitney-Wilcoxon test was used for data analysis.

Results: The study found a statistically significant 23-fold increase in the burden of alcoholism across 8 groups in 160 countries. Burden of 9 types of cancer (a - Trachea, bronchus, lung cancers, Stomach cancer and Colon and rectum cancers; b - Prostate cancer, Leukaemia and Pancreas cancer; c - Oesophagus cancer, Melanoma and other skin cancers, and Breast cancer) in 8 groups of countries increased by 1.5 - 3 times in parallel with the growth of the alcoholism gradient, the increase in the consumption of strong alcohol, cigarettes and animal products. The burden of 5 types of cancer (d - Liver cancer, Lymphomas, multiple myeloma, Mouth and oropharynx cancers, Bladder cancer and other neoplasms) decreased by 3 - 4 times as the alcoholism gradient increased and was associated with viral infections. In parallel with the growth of the alcoholism gradient in countries, the characteristics of 8 types of metabolic syndrome predictors increased by 1.5 - 3 times: overweight and obesity (BMI ≥ 25 and 30 kg/m2), hyperlipidemia (≥ 5 and 6.2 mmol/L), hyperglycemia (≥ 7 mmol/L), blood pressure (≥ 140/90 mm Hg, without pharmacological correction and with correction) and low physical activity (≤ 60 min/day). The life expectancy of men was not statistically significantly different at the minimum and maximum burden of alcoholism.

However, the gender difference in life expectancy between men and women increased statistically significantly from 1st group of countries to 8th group of countries from 3 to 7 years. This was indicative of the loss of male LE as the alcoholism gradient increased.

Conclusion: The results show an increase in risk factors for the burden of 9 types of cancer and 8 types of predictors of metabolic syndrome in parallel with the increase in the alcoholism gradient in 180 countries.

Keywords: Alcoholism Gradient; Burden of 14 Types of Cancer; 8 Predictors of Metabolic Syndrome; Levels of Alcohol; Tobacco; Food Consumption; The Quality of Life

  1. Rehm J., et al. “The relationship between different dimensions of alcohol use and the burden of disease-an update”. Addiction6 (2017): 968-1001.
  2. Cheatley J., et al. “Tackling the cancer burden: the economic impact of primary prevention policies”. Molecular Oncology 3 (2021): 779-789.
  3. Bagnardi V., et al. “Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis”. British Journal of Cancer 3 (2015): 580-593.
  4. Arnold M., et al. “Global Burden of 5 Major Types of Gastrointestinal Cancer”. Gastroenterology 1 (2020): 335-349.
  5. Naudin S., et al. “Healthy lifestyle and the risk of pancreatic cancer in the EPIC study”. European Journal of Epidemiology10 (2020): 975-986.
  6. Brenner H and Chen C. “The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention”. British Journal of Cancer 7 (2018): 785-792.
  7. McGlynn KA., et al. “Epidemiology of Hepatocellular Carcinoma”. Hepatology 73-1.1 (2021): 4-13.
  8. Liu Z., et al. “The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention”. Journal of Hepatology 4 (2019): 674-683.
  9. Sagnelli E., et al. “Epidemiological and etiological variations in hepatocellular carcinoma”. Infection 1 (2020): 7-17.
  10. Massarweh NN and El-Serag HB. “Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma”. Cancer Control 3 (2017): 1073274817729245.
  11. Rider JR., et al. “Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up”. European Urology 6 (2016): 974-982.
  12. Cohen N., et al. “Epidemiology and Demographics of the Head and Neck Cancer Population”. Oral and Maxillofacial Surgery Clinics of North America 4 (2018): 381-395.
  13. Abati S., et al. “Oral Cancer and Precancer: A Narrative Review on the Relevance of Early Diagnosis”. International Journal of Environmental Research and Public Health 24 (2020): 9160.
  14. Rivera C. “Essentials of oral cancer”. International Journal of Clinical and Experimental Pathology 9 (2015): 11884-11894.
  15. Kumar M., et al. “Oral cancer: Etiology and risk factors: A review”. Journal of Cancer Research and Therapeutics 2 (2016): 458-463.
  16. Tahbaz R., et al. “Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition”. Current Opinion in Urology 1 (2018): 62-79.
  17. Chow WH., et al. “Epidemiology and risk factors for kidney cancer”. Nature Reviews Urology 5 (2010): 245-257.
  18. Alba Rocco., et al. “Alcoholic disease: liver and beyond”. World Journal of Gastroenterology 40 (2014): 14652-14659.
  19. Wiseman MJ. “Nutrition and cancer: prevention and survival”. British Journal of Nutrition 5 (2019): 481-487.
  20. Clinton SK., et al. “The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future Directions”. Journal of Nutrition 4 (2020): 663-671.
  21. Vieira AR., et al. “Foods and beverages and colorectal cancer risk: a systematic review and meta-analysis of cohort studies, an update of the evidence of the WCRF-AICR Continuous Update Project”. Annals of Oncology 8 (2017): 1788-1802.
  22. Teegarden D., et al. “Redefining the impact of nutrition on breast cancer incidence: is epigenetics involved?” Nutrition Research Reviews 1 (2012): 68-95.
  23. Wang YH., et al. “Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies”. Molecular Psychiatry 7 (2020): 1487-1499.
  24. Kotkowski E., et al. “A neural signature of metabolic syndrome”. Human Brain Mapping 12 (2019): 3575-3588.
  25. Bishehsari F., et al. “Circadian rhythms and the gut microbiota: from the metabolic syndrome to cancer”. Nature Reviews Endocrinology 12 (2020): 731-739.
  26. Anstee QM., et al. “From NASH to HCC: current concepts and future challenges”. Nature Reviews Gastroenterology and Hepatology 7 (2019): 411-428.
  27. Islami F., et al. “Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States”. CA: A Cancer Journal for Clinicians 1 (2018): 31-54.
  28. World Health Organization. The global burden of disease: 2004 update. Geneva, WHO (2008).
  29. United Nations Department of Economic and Social Affairs/Population Division. 2009. World Population Prospects (2008).
  30. World Health Organization. Average daily ambient ultraviolet radiation (UVR) level. World Health Data Platform/GHO/Indicator Metadata Registry List Average daily ambient ultraviolet radiation (UVR) level (2004).
  31. World Population Prospects United Nations. 2005-2010.
  32. Bhaven N Sampat. “MPhil Academic Patents and Access to Medicines in Developing Countries”. American Journal of Public Health 1 (2009): 9-17.
  33. Gross National Happiness Commission. Royal Government of Bhutan.
  34. Global Health Observatory (GHO) data; Indicator and Measurement Registry version 1.7.0 BMI≥25; total cholesterol ≥ 5.0; blood glucose ≥ 7.0; insufficiently active. 2008//WHO (World Health Organization) Percentage of defined population Program Country (2008).
  35. Food and Agriculture Organization of the United Nations. Food Balance Sheets 2003-05.
  36. Treskov VG., et al. “[Clinical pharmacokinetics of mebikar. Computation of individual dosage regimens]”. Farmakologiia i Toksikologiia 1 (1985): 46-48.
  37. Treskov VG., et al. “[Plasma levels of biogenic amines in patients with various forms of the alcohol abstinence syndrome]”. Zh Nevropatol Psikhiatr Im S S Korsakova 2 (1989): 109-111.
  38. Radkevich LA and Radkevich DA. “C Comparative Analysis of Economic, Geographic, Social and Nutritional Risk Factors 4 Types of Non-Communicable Chronic Diseases (Melanoma, Multiple Sclerosis, Diabetes Mellitus and Hypertensive Heart Disease) in the Mediterranean and Caribbean Countries (Population Study)”. Journal of Obesity and Chronic Diseases 2 (2020): 51-58.
  39. Ludmila Radkevich and Dariya Radkevich. “Can Alcohol and Obesity be Considered Risk Factors for Diabetes Mellitus? (environmental study)”. Current Research in Diabetes and Obesity Journal 1 (2021): 555905.
  40. Rylkova D., et al. “Deficit in brain reward function and acute and protracted anxiety-like behavior after discontinuation of a chronic alcohol liquid diet in rats”. Psychopharmacology 3 (2009): 629-640.
  41. Gondré-Lewis MC., et al. “Pre-clinical models of reward deficiency syndrome: A behavioral octopus”. Neuroscience and Biobehavioral Reviews 115 (2020): 164-188.
  42. Angela M Wood., et al. “Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies”. The Lancet 10129 (2018): P1513-1523.
  43. Verbrugge LM and Wingard DL. “Sex differentials in health and mortality”. Women and Health 2 (1987): 103-145.
  44. Waldron I. “What do we know about causes of sex differences in mortality? A review of the literature”. Population Bulletin of the United Nations 18 (1985): 59-76.
  45. Verbrugge LM and Wingard DL. “Sex differentials in health and mortality”. Women and Health 2 (1987): 103-145.
  46. Trias-Llimós S and Janssen F. “Alcohol and gender gaps in life expectancy in eight Central and Eastern European countries”. The European Journal of Public Health 4 (2018): 687-692.
  47. Manso C. “[Alcohol and resistance to infections]”. Acta Médica Portuguesa 3 (2001): 343-348.
  48. Charostad J., et al. “DNA methyltransferases in virus-associated cancers”. Reviews in Medical Virology 2 (2019): e2022.

Ludmila Radkevich and Dariya Radkevich. Metabolic Syndrome Predictors and Cancer Incidence against the Backdrop of a Rising Gradient in the Burden of Alcoholism in Men in 160 Countries 2004. EC Pharmacology and Toxicology 11.3 (2023): 28-58.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.uk